{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000038","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.491260+00:00","generated_at":"2026-06-02T10:47:41.177209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros Q1 net loss widens to $43.1M; cash $442.4M, runway into 2027","bullets":["Net loss of $43.1M in Q1 2024 vs $35.8M in Q1 2023, driven by higher R&D spending.","R&D expenses $38.3M (up $7.2M YoY) reflecting pipeline advancement and manufacturing.","Cash and equivalents $442.4M as of March 31, up from $331.1M at year-end.","KER-050 Phase 3 MDS trial design discussed with FDA; update expected mid-2024.","KER-012 TROPOS Phase 2 PAH trial update anticipated in Q2 2024; ATS poster in May."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000038","json":"https://secwatch.observer/filing/0001664710-24-000038.json","markdown":"https://secwatch.observer/filing/0001664710-24-000038.md","text":"https://secwatch.observer/filing/0001664710-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/0001664710-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/kros-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:47:41.177209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb981ef21cf4e8225ca534d49224c2c9de67712e","claim":"Keros Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income net loss of $43.1 million.","evidence_excerpt":"Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/0001664710-24-000038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $43.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}